Analysis and Commentary STEVEN GROSSMAN 6/21/24 Analysis and Commentary STEVEN GROSSMAN 6/21/24 Two Pathways for Saving FDA’s FY 25 Budget Read More Analysis and Commentary STEVEN GROSSMAN 6/14/24 Analysis and Commentary STEVEN GROSSMAN 6/14/24 The Past is Prologue, But Subcommittee Bills May Not Be Read More Analysis and Commentary STEVEN GROSSMAN 6/7/24 Analysis and Commentary STEVEN GROSSMAN 6/7/24 What the FY 24 Appropriations Cycle Tells Us About FY 25 Read More Analysis and Commentary STEVEN GROSSMAN 5/31/24 Analysis and Commentary STEVEN GROSSMAN 5/31/24 “Hurry Up and Wait” and Other Appropriations Questions Read More Analysis and Commentary STEVEN GROSSMAN 5/17/24 Analysis and Commentary STEVEN GROSSMAN 5/17/24 Three Things We Heard in Senate-side Hill Meetings Read More Analysis and Commentary STEVEN GROSSMAN 5/10/24 Analysis and Commentary STEVEN GROSSMAN 5/10/24 Three Things We Heard in House-side Hill Meetings Read More Analysis and Commentary STEVEN GROSSMAN 5/3/24 Analysis and Commentary STEVEN GROSSMAN 5/3/24 Q&A on the Urgent Need for FDA Advocacy Read More Analysis and Commentary STEVEN GROSSMAN 4/26/24 Analysis and Commentary STEVEN GROSSMAN 4/26/24 Escaping the Downward Budget Pressures in FY 25 Read More Analysis and Commentary STEVEN GROSSMAN 4/19/24 Analysis and Commentary STEVEN GROSSMAN 4/19/24 The Alliance’s FY 25 Ask: Urgent Initiatives That Need More Funding Read More Analysis and Commentary STEVEN GROSSMAN 4/12/24 Analysis and Commentary STEVEN GROSSMAN 4/12/24 Alliance’s FY 25 Appropriations Request: Realistic for Meeting FDA’s Needs Read More Analysis and Commentary STEVEN GROSSMAN 4/5/24 Analysis and Commentary STEVEN GROSSMAN 4/5/24 President’s FY25 Budget Request: FDA Needs More Read More Analysis and Commentary STEVEN GROSSMAN 3/22/24 Analysis and Commentary STEVEN GROSSMAN 3/22/24 Preparing for the Alliance’s FY 25 “Ask” Read More Analysis and Commentary STEVEN GROSSMAN 3/15/24 Analysis and Commentary STEVEN GROSSMAN 3/15/24 Q&A About FDA Funding in FY 24 and FY 25 Read More Analysis and Commentary STEVEN GROSSMAN 3/8/24 Analysis and Commentary STEVEN GROSSMAN 3/8/24 Looking Ahead to the President’s FY25 Budget Request Read More Analysis and Commentary STEVEN GROSSMAN 3/1/24 Analysis and Commentary STEVEN GROSSMAN 3/1/24 Budget Angles: “Not All User Fees Are Alike” and “No Base, No Clarity” Read More Analysis and Commentary STEVEN GROSSMAN 2/23/24 Analysis and Commentary STEVEN GROSSMAN 2/23/24 5 Things to Know About the FY 24 Appropriations Endgame Read More Analysis and Commentary STEVEN GROSSMAN 2/16/24 Analysis and Commentary STEVEN GROSSMAN 2/16/24 Urging Members of Congress to Request Strong FDA Funding for FY 2025 Read More Analysis and Commentary STEVEN GROSSMAN 2/9/24 Analysis and Commentary STEVEN GROSSMAN 2/9/24 Developing the Alliance’s FY 2025 Recommendations Read More Analysis and Commentary STEVEN GROSSMAN 2/2/24 Analysis and Commentary STEVEN GROSSMAN 2/2/24 FY 24 Funding Is Not Settled; Yet FY 25 Is Coming Soon Read More Analysis and Commentary STEVEN GROSSMAN 1/26/24 Analysis and Commentary STEVEN GROSSMAN 1/26/24 Status of FY 24 and FY 25 Funding for FDA: Addressing Some FAQs Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 6/21/24 Analysis and Commentary STEVEN GROSSMAN 6/21/24 Two Pathways for Saving FDA’s FY 25 Budget Read More
Analysis and Commentary STEVEN GROSSMAN 6/14/24 Analysis and Commentary STEVEN GROSSMAN 6/14/24 The Past is Prologue, But Subcommittee Bills May Not Be Read More
Analysis and Commentary STEVEN GROSSMAN 6/7/24 Analysis and Commentary STEVEN GROSSMAN 6/7/24 What the FY 24 Appropriations Cycle Tells Us About FY 25 Read More
Analysis and Commentary STEVEN GROSSMAN 5/31/24 Analysis and Commentary STEVEN GROSSMAN 5/31/24 “Hurry Up and Wait” and Other Appropriations Questions Read More
Analysis and Commentary STEVEN GROSSMAN 5/17/24 Analysis and Commentary STEVEN GROSSMAN 5/17/24 Three Things We Heard in Senate-side Hill Meetings Read More
Analysis and Commentary STEVEN GROSSMAN 5/10/24 Analysis and Commentary STEVEN GROSSMAN 5/10/24 Three Things We Heard in House-side Hill Meetings Read More
Analysis and Commentary STEVEN GROSSMAN 5/3/24 Analysis and Commentary STEVEN GROSSMAN 5/3/24 Q&A on the Urgent Need for FDA Advocacy Read More
Analysis and Commentary STEVEN GROSSMAN 4/26/24 Analysis and Commentary STEVEN GROSSMAN 4/26/24 Escaping the Downward Budget Pressures in FY 25 Read More
Analysis and Commentary STEVEN GROSSMAN 4/19/24 Analysis and Commentary STEVEN GROSSMAN 4/19/24 The Alliance’s FY 25 Ask: Urgent Initiatives That Need More Funding Read More
Analysis and Commentary STEVEN GROSSMAN 4/12/24 Analysis and Commentary STEVEN GROSSMAN 4/12/24 Alliance’s FY 25 Appropriations Request: Realistic for Meeting FDA’s Needs Read More
Analysis and Commentary STEVEN GROSSMAN 4/5/24 Analysis and Commentary STEVEN GROSSMAN 4/5/24 President’s FY25 Budget Request: FDA Needs More Read More
Analysis and Commentary STEVEN GROSSMAN 3/22/24 Analysis and Commentary STEVEN GROSSMAN 3/22/24 Preparing for the Alliance’s FY 25 “Ask” Read More
Analysis and Commentary STEVEN GROSSMAN 3/15/24 Analysis and Commentary STEVEN GROSSMAN 3/15/24 Q&A About FDA Funding in FY 24 and FY 25 Read More
Analysis and Commentary STEVEN GROSSMAN 3/8/24 Analysis and Commentary STEVEN GROSSMAN 3/8/24 Looking Ahead to the President’s FY25 Budget Request Read More
Analysis and Commentary STEVEN GROSSMAN 3/1/24 Analysis and Commentary STEVEN GROSSMAN 3/1/24 Budget Angles: “Not All User Fees Are Alike” and “No Base, No Clarity” Read More
Analysis and Commentary STEVEN GROSSMAN 2/23/24 Analysis and Commentary STEVEN GROSSMAN 2/23/24 5 Things to Know About the FY 24 Appropriations Endgame Read More
Analysis and Commentary STEVEN GROSSMAN 2/16/24 Analysis and Commentary STEVEN GROSSMAN 2/16/24 Urging Members of Congress to Request Strong FDA Funding for FY 2025 Read More
Analysis and Commentary STEVEN GROSSMAN 2/9/24 Analysis and Commentary STEVEN GROSSMAN 2/9/24 Developing the Alliance’s FY 2025 Recommendations Read More
Analysis and Commentary STEVEN GROSSMAN 2/2/24 Analysis and Commentary STEVEN GROSSMAN 2/2/24 FY 24 Funding Is Not Settled; Yet FY 25 Is Coming Soon Read More
Analysis and Commentary STEVEN GROSSMAN 1/26/24 Analysis and Commentary STEVEN GROSSMAN 1/26/24 Status of FY 24 and FY 25 Funding for FDA: Addressing Some FAQs Read More
